You are about to be taken to a third-party site. The content on this site is for informational use only. Immunocine does not endorse any of the information, products, or services on third-party sites, and no information on third-party sites should be construed as an endorsement or recommendation of specific Immunocine products. By clicking on the link below, you consent to be directed to external material.Proceed Cancel
In the late 1800’s Dr. William Coley stumbled onto an interesting observation, that an active immune response in the area of a tumor could delay and even occasionally eliminate a cancerous threat1, 2. Though he didn’t fully understand the mechanisms at that time, he essentially demonstrated the power of the immune system even against a threat as tough as cancer. And though these “toxins” were occasionally able to generate a successful response, the underpinnings were still obscure and not practical to mainstream medicine. This left the door open for simpler paradigms, such as chemotherapy and radiation, to lead the efforts in the fight against cancer3. Though rife with failure and collateral damage, these remain the leading options even today.
Although it took roughly 100 years, utilization of the immune system against cancer began to garner more attention as A) chemotherapies continued to struggle against a variety of diseases and B) the scientific field had gained a better understanding of the cells and mechanisms powering the immune response. Within the first decade of the 2000s, a couple of pivotal clinical trials in which nothing more than removing a “brake” that turns off an immune response was pharmacologically blocked – raising the survival rate from 0% (with chemo) to about 5-10% in very fatal cancers – reinvigorated the field4, 5. This may initially seem disappointing and low until one realizes the promise held within such a result. If a non-specific immune system “booster” could do in 10 years what chemotherapy had been unable to do in 100, then the sky is the limit as we continue to study and understand the true power of our immunity. The immune system canfight back and win against cancer. Paradigms shift.
It is important to understand that “immunotherapy” is a broad category encompassing all that angles to educate and empower a patient’s own immune system to destroy cancerous tissue. There is not one type any more than there is one type of chemotherapy or one type of “medicine.” Some of the more common types of immunotherapy today include checkpoint inhibitors, CAR-T cells, antibodies, and Dendritic Cell Vaccines.
Checkpoint inhibitors, such as against “immune breaks” CTLA-4 and PD-1, interfere with a tumor’s ability to dampen an attacking immune response. By being effectively blocked from pressing the immune cell “off” switch, the immune response can act longer and stronger6, 7.
CAR-T cells are a patient’s own T cells that have been genetically modified in the laboratory to “shortcut” the natural immune system and engender a Killer T cell response against a specific marker expressed on the tumor.
Antibodies are drugs that essentially have 2 functional ends, 1 end targets something expressed on the cancer and the other end recruits immune cells to the site in hopes of introducing an immune attack.
Dendritic Cell Vaccines are the attempt to utilize the natural immune system pathways to generate a global, multi-faceted, and ongoing immune response capable of widespread surveillance and destruction of all cancerous cells.
Since showing effectiveness in treating cancer, there have been a variety of different clinical trials launched to continue to study the impact that may be possible with immunotherapy. Within the past decade, over 600 trials have been completed for checkpoint inhibitors alone, with another 1800 studies listed as of today, and this is but one immunotherapy modality44. As successes continue to accumulate across the spectrum, it is expected that this number will grow and eventually overtake chemotherapeutic trials.
As with any treatment, patients have a right to be aware of the potential side effects and what may be expected in general. Every patient is unique and therefore effects experienced can be different between individuals undergoing the same treatment, but there are a few generally shared traits that can and should be discussed.
To begin, most immunotherapies will share common symptoms of an “immune response” which can include things such as fever, chills, muscle aches, fatigue, swollen lymph nodes, swollen tumors, inflammation, nausea, appetite changes, and the sort45, 46. Essentially, the therapy is activating or educating a patient’s own immune system to begin destroying the cancer the same way it would destroy an invading pathogen. And eliminating a pathogen that is beyond the introductory stage usually is accompanied with symptomatic evidence of an immune response. Are these side effects? Or rather just the effects of a functioning immune system finally attempting to fight back the cancer?
As a note, within many trials and publications these symptoms may be classified as “Adverse Events (AEs),” which can sometimes scare people who imagine AE’s must refer to things such as
stroke, paralysis, and death. AEs are extremely important to track to understand how dangerous a treatment option may be, and until any particular event (a.k.a. symptom) is linked to a positive clinical outcome, it must be considered “Adverse.” But a runny nose can be considered adverse, and this alone should not deter patient’s from exploring these treatment options.
Other than these “natural” symptoms or side effects, the rest of the profile may boil down to the specific type of immunotherapy and to any underlying condition a patient may present with. For example, immune checkpoint inhibitors tend to boost the entire immune response and not just a response against the cancer. This can lead to off-target inflammation and truly erroneous outcomes. However a therapy such as Dendritic Cell Vaccine tends to be far more targeted and specific and thus off-target effects are minimal. This is not to imply there are no risks at all, but as with any treatment option at this juncture, the benefits must be weighed against the risk potential.
In general, the concept of Immunotherapy is simple: Empowering your own immune system to do what it normally does – protect you from a threat. And although the overarching principles of such a cancer treatment have been bandied about for over a hundred years, a lack of scientific understanding impeded real progress for much of that time. However as science has continued to evolve, new treatment options are becoming more mainstream. In many a sense, immunotherapy has been able to accomplish more in the past ten years for many fatal cancers than chemotherapy has been able to do in a hundred. The immunotherapy side effect profiles are more biological than toxic (as is the case with non-specific and often barbaric treatments), the chances to avoid relapse are significantly improved with an educated and functional immune system, and many scientists and doctors are -for the first-time- truly believing that cancer can be relegated to nothing more than an annoyance akin to the flu. There is still much to be done and much to be learned, but it is becoming more and more obvious that we are finally on the right track in our ongoing battle with cancer. Our own immune system failed in the first place and allowed cancer to grow and take over, so reprogramming our own immune system to correct its own mistake is an ideal and elegant solution with treatment capabilities never previously observed. The future is fast approaching.
1. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J26, 154-158 (2006).
2. Hoption Cann, S.A., van Netten, J.P. & van Netten, C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79, 672-680 (2003).
3. DeVita, V.T., Jr. & Chu, E. A history of cancer chemotherapy. Cancer Res 68, 8643-8653 (2008).
4. Alexander, W. The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. P T 41,185-191 (2016).
5. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723 (2010).
6. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11, 3801 (2020).
7. Jacob, J.B., Jacob, M.K. & Parajuli, P. Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol 91, 111-139 (2021).
8. Zaretsky, J.M. et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 375, 819-829 (2016).
9. Barrueto, L. et al. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Transl Oncol 13, 100738 (2020).
10. Johnson, D.B., Nebhan, C.A., Moslehi, J.J. & Balko, J.M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19, 254-267 (2022).
11. Spiers, L., Coupe, N. & Payne, M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford) 58, vii7-vii16 (2019).
12. D’Aloia, M.M., Zizzari, I.G., Sacchetti, B., Pierelli, L. & Alimandi, M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis 9, 282 (2018).
13. Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 12, 81 (2021).
14. Sterner, R.C. & Sterner, R.M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11,69 (2021).
15. Zhang, Y. et al. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity”. Front Immunol 12, 799206 (2021).
16. Bonifant, C.L., Jackson, H.J., Brentjens, R.J. & Curran, K.J. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3, 16011 (2016).
17. Lyman, G.H., Nguyen, A., Snyder, S., Gitlin, M. & Chung, K.C. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open 3, e202072 (2020).
18. Keating, S.J., Gu, T., Jun, M.P. & McBride, A. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States. Transplant Cell Ther 28, 404 e401-404 e406 (2022).
19. Cruz, E. & Kayser, V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics 13, 33-51 (2019).
20. Sun, A. & Benet, L.Z. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Pharmacology 105, 145-163 (2020).
21. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16, 2825-2833 (1998).
22. Benavente, S. et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15, 1585-1592 (2009).
23. Ahmad, A. Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. Adv Exp Med Biol 1152, 217-228 (2019).
24. Mishima, Y. et al. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J 1, e15 (2011).
25. Patel, D. et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 27, 3355-3366 (2007).
26. Calmeiro, J. et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics 12 (2020).
27. Yu, J., Sun, H., Cao, W., Song, Y. & Jiang, Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 11, 3 (2022).
28. Nava, S. et al. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients. Stem Cells Transl Med 4, 1164-1172 (2015).
29. Anguille, S., Smits, E.L., Lion, E., van Tendeloo, V.F. & Berneman, Z.N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15, e257-267 (2014).
30. Rob, L. et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer 10 (2022).
31. Caro, A.A., Deschoemaeker, S., Allonsius, L., Coosemans, A. & Laoui, D. Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. Cancers (Basel) 14 (2022).
32. Konduri, V. et al. Chemo-immunotherapy mediates durable cure of orthotopic Kras(G12D)/p53(-/-) pancreatic ductal adenocarcinoma. Oncoimmunology 5, e1213933 (2016).
33. Konduri, V. et al. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. Cancer Gene Ther 26, 282-291 (2019).
34. Gardner, A., de Mingo Pulido, A. & Ruffell, B. Dendritic Cells and Their Role in Immunotherapy. Front Immunol11, 924 (2020).
35. Hole, C.R. et al. Induction of memory-like dendritic cell responses in vivo. Nat Commun 10, 2955 (2019).
36. Silva, M.O. et al. Antigen Delivery to DEC205(+) Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites. Int J Biol Sci 17, 2944-2956 (2021).
37. Zammit, D.J., Cauley, L.S., Pham, Q.M. & Lefrancois, L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 22, 561-570 (2005).
38. Halpert, M.M. et al. MHC class I and II peptide homology regulates the cellular immune response. FASEB J 34,8082-8101 (2020).
39. Qian, C. & Cao, X. Dendritic cells in the regulation of immunity and inflammation. Semin Immunol 35, 3-11 (2018).
40. Wculek, S.K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20, 7-24 (2020).
41. Chan, C.W. & Housseau, F. The ‘kiss of death’ by dendritic cells to cancer cells. Cell Death Differ 15, 58-69 (2008).
42. Rolinski, J. & Hus, I. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy. J Immunotoxicol 11, 311-318 (2014).
43. Halpert, M.M. et al. Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. Stem Cells Dev 25, 774-787 (2016).
44. Pala, L. et al. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 5, e2226252 (2022).
45. Brown, T.J., Mamtani, R. & Bange, E.M. Immunotherapy Adverse Effects. JAMA Oncol 7, 1908 (2021).
46. Barber, F.D. Adverse Events of Oncologic Immunotherapy and Their Management. Asia Pac J Oncol Nurs 6, 212-226 (2019).
May 16, 2023
March 15, 2023
March 12, 2023